6 studies published long-term survival data of cancer patients

At the time of the annual ASCO data harvest, the industry generally reflects that this year is a small year for ASCO, with few refreshing projectsThis year, however, coincides with the fifth anniversary of the first PD-1's global approval, and keytruda's five-year lung cancer survival data is also releasedFor cancer patients, 5-year long-term survival can be regarded as "cure"For most cancer drugs, it is an excellent performance to bring 3-year long-term survival to patientsSo what therapies have published 3-5 long-term survival data in this ASCO? How about OS, PFS and DFS? < br / > 1Oxitinib < br / > cancer species: NSCLC < br / > Abstract No.: e20560 < br / > Test Code: stage III flaura test (nct02296125) < br / > 3-year overall survival rate: 57.3% (95% CI, 46.6% - 69.2%) < br / > 5-year overall survival rate: 31.1% (95% CI, 23.7% - 41.8%) < br / > research significance: the 3-year and 5-year survival rates of gefitinib or erlotinib, the first generation EGFR inhibitor, were 41.1% (95% CI: 31.9% - 52.9%) and 15.5% (95% CI: 11.6% - 22.1%), respectivelyThe 5-year survival rates of patients with advanced NSCLC of egfrm treated with oxotinib were twice that of gefitinib or erlotinib (31.1% vs 15.5%)The long-term follow-up data of flaura (OS maturity of 60%) will further verify this result< br / > 2Dabrafenib + traceinib < br / > cancer species: Patients with unresectable or metastatic melanoma of brafv600 mutant < br / > Abstract No.: 9507 < br / > Test Code: phase III combi-d study (nct01584648); < br / > 4-year progression free survival rate: 21% (95% CI, 17% - 24%) < br / > 4-year total survival rate: 37% (95% CI, 33% - 42%) < br / > Test Code: combi-v study (nct01597908) < br / > 5-year progression free survival rate: 19% (95% CI, 15% - 22%) < br / > 5-year overall survival rate: 34% (95% CI, 30% - 38%) < br / > research significance: for many patients with unresectable or metastatic melanoma of brafv600 mutant, first-line treatment with D + T can obtain long-term benefits< br / > 3Ofatumab + NBR < br / > cancer species: chronic lymphocytic leukemia (CLL) < br / > Abstract No.: e20560 < br / > Test Code: complete 1 (nct00748189) < br / > 5-year total survival rate: 68.5% (95% CI, 61.5% - 74.5%) < br / > 5-year total survival rate (CHL group): 65.7% (95% CI, 58.6% - 71.9%)< br / > significance: this 5-year survival follow-up analysis supports the results of the preliminary analysisCompared with the Chl group, the OS and PFS in the ofa + CHL group decreased by 12% (not significant) and 39% respectivelyNo new safety issues were observed in the ofa + CHL group< br / > 4Rituximab < br / > cancer species: Patients with diffuse large B-cell lymphoma < br / > abstract number: 7507 < br / > 5-year disease-free survival (DFS) rate: 79% (observation rate: 74%) < br / > research significance: Rituximab maintenance therapy has no additional benefit in DLBCL patients with first CR after R-CHOP< br / > 5Durvalumab < br / > cancer species: unresectable stage III NSCLC patients < br / > Abstract No.: 8526 < br / > Test Code: stage III Pacific study < br / > 3-year overall survival rate: 66.3% vs 43.5%< br / > research significance: updated the OS data of Pacific, including 3-year survival rate, emphasized the long-term clinical benefits of durvalumab after radiotherapy and chemotherapy, and further established the Pacific program as the nursing standard of the population< br / > 6Pabolizumab < br / > cancer species: advanced NSCLC < br / > Abstract No.: lba9015 < br / > Test Code: keynote-001 (nct01295827) < br / > 5-year total survival rate (TPS ≥ 50%): 29.6% < br / > research significance: the first group of patients who participated in kn001 test of drug K has been observed for more than 5 yearsThe mortality of advanced NSCLC was high, and the 5-year survival rate before PD-1 was only 5%< br / > as the first-line drug, pembrolizumab released by ASCO in 2019 has a 5-year survival rate of 23% and nearly 30% in patients with high expression of PD-1 (TPS ≥ 50%)The 5-year survival rate was 15.5% in the first-line chemotherapy patients and 25% in the patients with high expression of PD-1 (TPS ≥ 50%)This is a fundamental improvement in the treatment of advanced lung cancer.